

Recommendations

- Consider the patient's full medical history, including any prior or concurrent biological medicine use.
- There is no clinical trial experience with ENTYVIO in patients previously treated with natalizumab. Given the known risk of PML development in patients with previous natalizumab exposure, physicians should normally wait 12 weeks after the last natalizumab dose prior to initiating ENTYVIO treatment.
- Patients treated with ENTYVIO should be monitored for any new onset or worsening of neurological signs and symptoms such as those listed below:
 - Progressive weakness on one side of the body or clumsiness of limbs
 - Disturbance of vision
 - Changes in thinking, memory and orientation, leading to confusion and personality changes
- Any patients with new onset or worsening signs and symptoms suggestive of PML should be considered for neurological referral at a centre equipped to diagnose PML.



ITEM CODE: EUCAN/VED/2014-10032
Date of preparation: 17-04-2023

Important Safety Information



Using ENTYVIO for Patients with Ulcerative Colitis or Crohn's Disease

ENTYVIO (vedolizumab) is a gut-selective, humanised monoclonal antibody that is indicated for use in adult patients with either moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) who had an inadequate response with, lost response to, or were intolerant to either conventional UC or CD therapies or a tumour necrosis factor-alpha (TNF α) antagonist. In addition, Entyvio (vedolizumab) is also indicated for use in adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for UC, and have had an inadequate response with or lost response to antibiotic therapy.

IMPORTANT SAFETY INFORMATION

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal opportunistic infection of the central nervous system that has been associated with the use of Tysabri® (natalizumab, $\alpha 4\beta 7$ and $\alpha 4\beta 1$ integrin antagonist), which is indicated for use in patients with multiple sclerosis. It is hypothesised that the risk for PML with natalizumab is primarily due to binding to the $\alpha 4\beta 1$ integrin which inhibits leukocyte migration and immunosurveillance of the CNS and not the binding to the $\alpha 4\beta 7$ integrin which inhibits migration of certain leukocytes to the gastrointestinal tract. However, the theoretical risk of PML with ENTYVIO cannot be excluded because ENTYVIO binds to the $\alpha 4\beta 7$ integrin.

There is no evidence of systemic or CNS immunosuppression with ENTYVIO. However, the theoretical risk of a patient treated with ENTYVIO developing PML cannot be excluded. Therefore, patients treated with ENTYVIO should be monitored for any new onset or worsening of neurological symptoms such as those listed below:

- Progressive weakness on one side of the body or clumsiness of limbs
- Disturbance of vision
- Changes in thinking, memory and orientation, leading to confusion and personality changes

Any patients with new or worsening signs and symptoms suggestive of PML should be considered for neurological referral at a centre

equipped to diagnose PML. If PML is suspected, treatment with ENTYVIO must be withheld; and if confirmed, treatment must be permanently discontinued. Suspected cases of PML should be reported to Takeda or directly to the Malta Medicines Authority.

Considerations before treating patients with previous natalizumab exposure

There is no clinical trial experience with ENTYVIO in patients previously treated with natalizumab. Since natalizumab has been associated with an increased risk of PML, physicians should normally wait 12 weeks after the last natalizumab dose prior to initiating treatment with ENTYVIO.

Prescribing ENTYVIO

Intravenous

ENTYVIO is administered as an intravenous infusion over 30 minutes and must be reconstituted and diluted prior to administration. ENTYVIO should not be administered intramuscularly or as an intravenous push or bolus.

Subcutaneous

After initiation with intravenous infusions, Entyvio can be administered by subcutaneous injections. The subcutaneous formulation is available as solution for injection in pre-filled syringe and pre-filled pen. Please refer to the [label](#) for more information.

Prior to treatment initiation patients should be advised on the potential benefits and risks of ENTYVIO. Patients should be provided the Patient Information Leaflet and the Patient Alert Card for ENTYVIO and have the opportunity to

read and ask questions. It is important that the patient's overall health be assessed at each infusion visit and any questions resulting from the patient's reading of the Patient Information Leaflet be discussed.

There is no clinical trial experience in patients concomitantly receiving biologic immunosuppressants. Therefore, the use of ENTYVIO in such patients is not recommended.

Reporting Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.

Report form can be downloaded from www.medicinesauthority.gov.mt/adrportal and sent by post or email to;
P: Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000, Malta

E: postlicensing.medicinesauthority@gov.mt

Alternatively, any suspected adverse reactions can be reported to the Takeda local distributor Drugsales Ltd on

E: safety@drugsalesltd.com or:

P: +356 21419070/1/2

Medicines Authority approval date: **17-04-2023**

Please see the accompanying full Prescribing Information and Patient Information Leaflet.